Adare Pharma Solutions

Articles

In the wake of the Food and Drug Administration's (FDA's) latest guidance on nitrosamine contamination, ensuring compliance and safeguarding pharmaceutical products is more critical than ever. This ebook provides a comprehensive roadmap for understanding nitrosamine risks and offers actionable strategies to mitigate potential impurities. Through expert insights from Adare Pharma Solutions, you’ll learn how to remain compliant, identify risks, and implement cutting-edge strategies for nitrosamine mitigation.

Nitrosamine Mitigation: A Path to Regulatory Compliance

How Adare Pharma Solutions is evolving to keep pace with changes in the industry.

Adare Pharma Solutions - Evolving to Meet the Future Needs of Customers

Oral solid dose capabilities and small molecule expertise

Recent and planned expansions in packaging, high potency, and controlled substances offerings as well as a new nitrosamine mitigation offering

Videos

When a large CDMO couldn’t give a mid-size pharma company the proper attention, Adare stepped in to help manufacture CTM batches and get their project to the clinic quickly.

Case Study: Meeting An Aggressive Go-To-Clinic Timeline

A discussion of the FDA's guidance on nitrosamine impurities, various approaches for reducing the presence of impurities, and how Adare's unique nitrosamine mitigation process can help products achieve compliance.

Nitrosamine Impurities Deadline: Are You Compliant?

In this article, gain insights into how early-stage pharmaceutical product development is foundational for successful clinical trials and regulatory approvals, and why collaboration with experienced partners like CDMOs is essential.

Streamline Early-Stage Development to Reach the Clinic Faster

To help improve adherence in children, drug developers need to consider innovative new dosage forms that can deliver flexible and convenient medications for young patients.
